Companies · Biotechnology

ONCoPEP, Inc.

NORTH ANDOVER · Biotechnology

Diligence memoA one-page analyst read on ONCoPEP, Inc. — recommendation, valuation, rhythm, risks.
$12.7M
Total raised · real
4
Rounds
1.1×
Latest step-up
Top 41%
Sector rank · raised
Seed
Latest stage · inferred · Tue May 06 2014 00:00:00 GMT+0000 (Coordinated Universal Time)

ONCoPEP, Inc. looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 2.30× the median modeled value of Seed Biotechnology companies in 2013–2015 (122 peers) — value vs value, same stage and era.
Dormant
  • Last raise 12.2 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

ONCoPEP, Inc. is one of 4291 Biotechnology companies tracked from NORTH ANDOVER. By capital raised it ranks mid-pack (ahead of 60% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeed · 2011-04-18 Raised $2.5M (real) Modeled valuation $112M (est)$2.5M$112MSeed2011Seed · 2011-04-18 Raised $3.6M (real) Modeled valuation $162M (est)$3.6M$162MSeed2011Seed · 2014-05-06 Raised $3.0M (real) Modeled valuation $135M (est)$3.0M$135MSeed2014Seed · 2014-05-06 Raised $3.5M (real) Modeled valuation $154M (est)$3.5M$154MSeed2014+$3.6M+$3.0M+$3.5MCumulative $13M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$2.5M · 2011
Seed extension$3.6M · 2011
Seed extension$3.0M · 2014
Seed extension$3.5M · 2014

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$153.5M
Base estimate est.
$2.5M
Conservative case
$1.2B
Upside case
$17.3M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $112.1M · 2011-04-182011Seed · modeled $162.1M · 2011-04-18Seed · modeled $134.9M · 2014-05-06Seed · modeled $153.5M · 2014-05-062014
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
6.0 yr
Elapsed time used
12.2 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
12 mo
Avg between rounds
$4.2M/yr
Capital velocity
15.2 yr
On record since
2011
First round
4
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.8× above median
This company$12.7M
Sector median$7.2M
Latest round — vs other Seed rounds in sector (real $, this stage) 2.0× above median
This company$3.5M
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 2.4× above median
This company$153.5M
Sector median$64.2M

Raised more than 60% of sector peers (real $). Modeled value above 67% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #9 of 122.

This companyCohort peer
$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Harpoon Medical, Inc. · Seed Raised $7.8M · modeled $173.2M (est)Admittance Technologies, Inc. · Seed Raised $3.9M · modeled $173.0M (est)Bell Biosystems, Inc. · Seed Raised $6.2M · modeled $169.2M (est)Nexstim Plc · Seed Raised $3.7M · modeled $166.4M (est)Iontera, Inc. · Seed Raised $16.8M · modeled $164.2M (est)Monteris Medical Inc · Seed Raised $9.0M · modeled $163.1M (est)Abzena plc · Seed Raised $4.3M · modeled $160.0M (est)Alkahest, Inc. · Seed Raised $3.5M · modeled $155.4M (est)Cal-X Stars Business Accelerator, Inc. · Seed Raised $3.4M · modeled $151.4M (est)QT Holdings Corp. · Seed Raised $3.8M · modeled $145.9M (est)Insight Genetics, Inc. · Seed Raised $5.5M · modeled $135.4M (est)ONCoPEP, Inc. (this company) Raised $12.7M · modeled $153.5M (est)ONCoPEP, Inc.
CompanyStageRaised · realValue · estvs peer med.
Harpoon Medical, Inc.Seed$7.8M$173.2M2.59×
Admittance Technologies, Inc.Seed$3.9M$173.0M2.59×
Bell Biosystems, Inc.Seed$6.2M$169.2M2.53×
Nexstim PlcSeed$3.7M$166.4M2.49×
Iontera, Inc.Seed$16.8M$164.2M2.46×
Monteris Medical IncSeed$9.0M$163.1M2.44×
Abzena plcSeed$4.3M$160.0M2.40×
Alkahest, Inc.Seed$3.5M$155.4M2.33×
ONCoPEP, Inc. this companySeed$12.7M$153.5M2.30×
Cal-X Stars Business Accelerator, Inc.Seed$3.4M$151.4M2.27×
QT Holdings Corp.Seed$3.8M$145.9M2.19×
Insight Genetics, Inc.Seed$5.5M$135.4M2.03×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$2.5M2011-04-18$12.6M$112.1M90%
Seed$3.6M2011-04-18$18.3M$162.1M90%
Seed$3.0M2014-05-06$15.2M$134.9M90%
Seed$3.5M2014-05-06$17.3M$153.5M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$2.5M2011-04-18
    • First recorded raise — entered as Seed.
  2. Seed$3.6M2011-04-18
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.4× larger than the prior — scaling up.
  3. Seed$3.0M2014-05-06
    • Raised again after 37 mo — slower than the ~14 mo sector norm.
    • Round roughly the size of the prior one.
  4. Seed$3.5M2014-05-06
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
Intelligence
2015 ~Q2
Modeled next raise · ~12mo cadence
$3.9M
Modeled next size est.range $3.5M$6.3M
1.1×
Last step-up
$4.2M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Marc Cohen5 other2011-04
Kenneth Anderson4 other2011-04
Elena Prokupets1 other2011-04
Bruce Downey2011-04
Doris Peterkin2011-04
Jay Eastman2014-05
Joslyn Dobson2011-04
Nikhil Munshi2011-04
Registry & provenance

ONCoPEP, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1519887
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Starton Therapeutics Inc.BiotechnologySeed$10.7M$8.8Mnetwork1 shared operator · same sector · same stage
Cambridge Endoscopic Devices IncBiotechnologySeed$12.0M$129.8Msame sector · same stage
Axogen CorpBiotechnologySeed$14.3M$133.2Msame sector · same stage
Window Therapeutics, Inc.BiotechnologySeries A$7.5M$57.2Mnetwork1 shared operator · same sector
Cambridge Heart IncBiotechnologySeed$10.2M$130.5Msame sector · same stage
Stimwave Technologies IncBiotechnologySeed$9.8M$132.9Msame sector · same stage
Iontera, Inc.BiotechnologySeed$16.8M$164.2Msame sector · same stage
Monteris Medical IncBiotechnologySeed$9.0M$163.1Msame sector · same stage
Frequently asked
How much funding has ONCoPEP, Inc. raised?
ONCoPEP, Inc. has raised approximately $12.7M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is ONCoPEP, Inc.'s estimated valuation?
Provath's modeled valuation for ONCoPEP, Inc. is approximately $153.5M (modeled range $2.5M–$1.2B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is ONCoPEP, Inc. at?
ONCoPEP, Inc.'s latest modeled financing stage is Seed. Its most recent recorded round closed around Tue May 06.
What does ONCoPEP, Inc. do and where is it based?
ONCoPEP, Inc. operates in the Biotechnology sector, based in NORTH ANDOVER.
Explore related

See where ONCoPEP, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at ONCoPEP, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.